Navigation Links
InterMune Reports Fourth Quarter And Full Year 2012 Financial Results And Business Highlights
Date:2/21/2013

ures before complete patient access to Esbriet is achieved.
  • Mid-Sized Countries (MSC) – In addition to the seven MSC for which Esbriet pricing has been secured, the company anticipates launches in the remaining three MSC of Netherlands, Finland and Ireland by mid-2013, assuming that acceptable pricing and reimbursement conditions are negotiated in these countries.
  • Enrollment of InterMune's Phase 3 pirfenidone study, ASCEND, in the United States and certain additional territories was completed in January 2013.  ASCEND is a double-blind, placebo-controlled trial of 52 weeks duration with a primary endpoint of change in forced vital capacity (FVC) between baseline and Week 52.  The trial enrolled IPF patients with mild-to-moderate impairment in lung function and certain characteristics that the company believes enhance the probability of a successful study outcome.  Top-line results are expected in Q2 of 2014.
  • On January 22, 2013, InterMune completed a public offering of 15,525,000 shares of its common stock, including the underwriters' over-allotment, with net proceeds to the company of $145.7 million (after payment of underwriting discounts and commissions, and expenses).  InterMune also completed a concurrent public offering of $120.75 million aggregate principal amount of the company's 2.50% convertible Senior Notes due 2017, including the Note underwriters' over-allotment, with net proceeds to the company of $116.7 million (after payment of the underwriting discounts and commissions, and expenses).  The company has used proceeds from the convertible notes offering to repurchase and cancel $66.6 million of its outstanding $85.0 million aggregate principal amount 2015 Notes, and intends to repurchase the remaining $18.4 million of the outstanding 2015 Notes over time.
  • On February 14, 2013 InterMune announced that Sean P. Nolan has joined the company as Executive Vice President and Chief B
    '/>"/>

  • SOURCE InterMune, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related biology technology :

    1. InterMune to Report Unaudited Fourth Quarter Esbriet® Revenue and Business Update on January 5
    2. InterMune to Present at J. P. Morgan Healthcare Conference
    3. InterMune to Release Fourth Quarter and Full Year Financial Results on February 9
    4. InterMune To Present At JMP Securities Healthcare Conference
    5. InterMune To Release Third Quarter Financial Results On November 7
    6. InterMune Reports Third Quarter 2012 Financial Results And Business Highlights
    7. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
    8. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
    9. Interleukin Genetics Reports Third Quarter 2011 Financial Results
    10. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
    11. Nile Therapeutics Reports 2011 Third Quarter Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/20/2014)... , Oct. 20, 2014  GenVec, Inc. (NASDAQ: ... Horovitz , Ph.D., from its board of directors effective on ... August 2003, and served as its chairman from June 2006 ... the Nominating and Corporate Governance and Audit Committees of the ... than a decade of dedicated service to GenVec, and its ...
    (Date:10/20/2014)... 20, 2014 OncLive® ... Cancer Center at Thomas Jefferson University has joined ... the Strategic Alliance Partnership program, the Sidney Kimmel ... to raise awareness of the Center’s cutting-edge research ... projects. Clinicians and other health care professionals from ...
    (Date:10/20/2014)... Local veterinary surgeon, Dr. Tim McCarthy is ... donor stem cells for dogs with osteoarthritis. Dr. McCarthy ... performed clinical stem cell therapy for 7 years. The ... a single injection of donor stem cells into one ... and inflammation in the treated joints. , Candidates ...
    (Date:10/19/2014)... 20, 2014 OCTOBER 20-22, ... (ABIM). ABIM will take place at ... about ABIM 2014 is now available at ... representing companies and organizations from all over ... information on the latest products and developments ...
    Breaking Biology Technology:Zola P. Horovitz To Retire From GenVec Board 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3Cascade Veterinary Referral Center Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2
    ... href="http://www.ambion.com/catalog/CatNum.php?1632"> Silencer , ... be readily adapted for labeling long dsRNA. ... for this application. See "<A , href="#visualizing">Visualizing ... experimintal data using dsRNA , labeled in ...
    ... , NAVIGATE THIS ARTICLE: <A , ... href="#3">RNA , Isolation, Probe Generation > <A , ... > <A , href="#5">Hybridization, , ... & Reprobing , , , , ...
    ... Ambion has ... siRNA synthesis and purification based on in vitro , ... (patent pending). This kit produces transfection-ready siRNA , ... researchers at the Salk Institute ...
    Cached Biology Technology:Fluorescently Labeling Long dsRNA with the Silencer siRNA Labeling Kit 2Fluorescently Labeling Long dsRNA with the Silencer siRNA Labeling Kit 3Fluorescently Labeling Long dsRNA with the Silencer siRNA Labeling Kit 4Northern Analysis: The Basics 2Northern Analysis: The Basics 3Northern Analysis: The Basics 4Northern Analysis: The Basics 5Northern Analysis: The Basics 6Northern Analysis: The Basics 7Northern Analysis: The Basics 8Northern Analysis: The Basics 9Northern Analysis: The Basics 10Northern Analysis: The Basics 11Northern Analysis: The Basics 12Northern Analysis: The Basics 13Northern Analysis: The Basics 14Northern Analysis: The Basics 15Northern Analysis: The Basics 16Northern Analysis: The Basics 17Northern Analysis: The Basics 18Northern Analysis: The Basics 19Your Data: Silencing Neural Cell Adhesion Genes with In Vitro Transcribed siRNAs 2
    (Date:10/17/2014)... of Copenhagen have shown for the first time how ... fibrosis patients, giving them the opportunity to get tremendous ... , The study also discovered the bacterial growth in ... halted or slowed down by the immune cells. The ... and helped "suffocate" the bacteria, forcing the bacteria to ...
    (Date:10/16/2014)... the bowel lining develops and, in the process, suggested ... The researchers produced evidence that stem cells are responsible ... feature of the bowel lining, and believe these stem ... finding as scientists are still divided on the stem ... Wee Tan and Professor Tony Burgess from the Walter ...
    (Date:10/15/2014)... PORT WASHINGTON, N.Y. , Oct. 15, 2014 ... in technology solutions for home and community-based care, ... the benefits of implementing Sandata,s Santrax® Electronic Visit ... Quality Care Services is a home health company ... Texas . ...
    Breaking Biology News(10 mins):Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2Cryptic clues drive new theory of bowel cancer development 2Sandata Announces Case Study with Quality Care Services, Inc. 2
    ... 2008) Bison can repopulate large areas from Alaska ... series of conservation and restoration measures are taken, according ... Wildlife Conservation Society and other groups. The assessment ... ranchers, and Native Americans/First Nations peoples, and appears in ...
    ... neurotoxin responsible for the deadly food poisoning disease ... facial wrinkles can also be used as a ... a billionth of an ounce can cause muscle paralysis ... exposure can inhibit the destructive action of this neurotoxin ...
    ... to turning plants into biofactories capable of producing oils ... manufacture a range of products. ,Scientists working within ... Initiative (CBI) have achieved a major advance by accumulating ... in the model plant, Arabidopsis. UFAs are usually ...
    Cached Biology News:Bison can thrive again, study says 2Scientists determine drug target for the most potent botulinum neurotoxin 2Boost for 'green plastics' from plants 2
    ... RPMI 1640 with 2 mM L-glutamine and harvested ... order to keep the antigens in their native ... cells are arrayed on a 12-well (5 mm) ... treated to enhance cellular attachment and to minimize ...
    Mouse polyclonal antibody to REXO4 - XPMC2 prevents mitotic catastrophe 2 homolog (Xenopus laevis)...
    CELLine System cultivation flask (for secreted products)...
    ... StabilCoat Plus Microsphere/Microarray Stabilizer is an ... protein and other non-toxic chemicals in a ... 7.4. This product contains a ... as a preservative. StabilCoat Plus Stabilizer ...
    Biology Products: